Haleon Corp (HLN) Kapitalizatsiyaning foydaga nisbati

Haleon Group (HLN) korporativ emblemasi va logotipi

Haleon plc gigiyena mahsulotlariga bo'lgan barqaror talab tufayli makroiqtisodiy zarbalarga yuqori chidamlilikni namoyish etmoqda. Kompaniyaning forward P/E ko'rsatkichi foydaga nisbatan bozor baholashining dinamikasini aniq ko'rsatadi, bunda 18.60 ushbu metrikaning joriy darajasini ifodalaydi. O'sish global mega-brendlarning yangi bozorlarga kengayishi hisobiga ta'minlanmoqda, samaradorlik esa zavodlaridagi qadoqlash liniyalarining avtomatlashtirilishi orqali saqlanib qolmoqda.

HLN: haleon.com P/E multiplikatori 28.04.2023 - 15.11.2026

Haleon plc kompaniyasining tahliliy kesimlari

- aksiya kursi va ekspertlarning narx prognozi:
Narxlar dinamikasi grafigi Haleon PLC|HLN - Maqsadli narxlar grafigi
- bozor kapitallashuvi tafsilotlari:
Bozor qiymati Haleon Corp|HLN - Kompaniyani butunlay sotib olishdagi haqiqiy narx
- xususiy kapitalning balans qiymati ko'rsatkichlari:
Aksiyaning balans narxi Haleon|HLN - Balans kapitallashuvi|Balans qiymatiga nisbatan bozor qiymati haleon.com|HLN - Kompaniyaning umumiy aktivlari
- qarz majburiyatlari va likvidlik statistikasi:
Qarzning kapitalga nisbati Haleon plc|HLN - Uzoq muddatli qarzning o'z kapitaliga nisbati|Qisqa muddatli qarzdorlikning kapitalga nisbati Haleon plc|HLN - Kompaniyaning jamlangan qarzlari|Qarzning sof aktivlarga nisbati Haleon PLC|HLN - Kompaniyaning uzoq muddatli qarzlari|Kompaniyaning qisqa muddatli qarzlari Haleon|Tezkor likvidlik haleon.com
- foyda va qiymat multiplikatorlari haqida ma'lumot:
HLN - Sof foyda|Kutilayotgan sof foyda Haleon plc|HLN - Narxning foydaga nisbati|Prognoz qilingan narx-foyda nisbati Haleon Corp|HLN - Narxning foydaga va o‘sish sur’atiga nisbati|Korxona qiymatining amortizatsiyadan oldingi operatsion foydaga nisbati Haleon Corp|HLN - Eskirish chegirilmasdan oldingi operatsion foyda|Sirpanuvchi yil uchun bir aksiya uchun foyda Haleon|HLN - So'nggi o'n ikki oy davomida bir aksiya uchun foyda|So'nggi o'n ikki oy davomida bir aksiya uchun sof foydaning yillik dinamikasi haleon.com|HLN - Joriy yilda bir aksiya uchun foyda o'sishi|Keyingi yil uchun bir aksiya uchun sof foyda o'sishi prognozi Haleon plc
- kompaniyaning sotuvlari va tushumi statistikasi:
HLN - Daromad va sotish hajmi|Kompaniyaning kelajakdagi sotish hajmi Haleon|HLN - P/S multiplikatori|Sotuvga nisbatan forvard narx Haleon Group|HLN - So'nggi o'n ikki oy davomida yillik sotuv o'sishi
Kompaniyaning jamlanma tahlili:Haleon - HLN
Haleon Corp original mahsuloti

Haleon plc (HLN) xavfsiz gigiyena mahsulotlarini ishlab chiqishga bo'lgan innovatsion yondashuvi orqali yuqori biznes qo'shimcha qiymatini yaratadi. P/E koeffitsiyenti joriy bozor ulushi narxini aksiya uchun sof foyda bilan bog'lagan holda ushbu samaradorlikni aks ettiradi. Ushbu metrika investitsiyalarning qoplanish muddatini va kelajakdagi o'sish uchun to'langan premium miqdorini belgilaydi. Haleon plc (HLN) ning P/E tebranishlarini tahlil qilish orqali investor aktivlarning haddan tashqari qimmat baholangan yoki past baholangan bosqichlarini o'z vaqtida aniqlashi mumkin.

Muhim raqobatchilar

P/E multiplikatori Kenvue Corp|Narx-foyda koeffitsiyenti VRNA (Verona Pharma Corp)|MENS (Jyong Bio) - Kompaniya qiymatining sof foydaga nisbati|Narxning foydaga nisbati Ligand Pharmaceuticals Incorporated LGND|Amneal (AMRX) - Kapitalizatsiyaning foydaga nisbati|PRGO: Narx-foyda koeffitsiyenti|Alvotech SA - Bozor narxining sof foydaga nisbati|LQDA: P/E multiplikatori|Galapagos Genomics - Kompaniya qiymatining sof foydaga nisbati|ANIP (ANI Pharmaceuticals Inc) - P/E multiplikatori|Kapitalizatsiyaning foydaga nisbati mannkindcorp.com MNKD|Narxning foydaga nisbati Amphastar Pharmaceuticals, Inc. (AMPH)|PCRX (Pacira Pharmaceuticals) - Kompaniya qiymatining sof foydaga nisbati|P/E multiplikatori SPRY (ARS Pharmaceuticals Inc)|Bozor narxining sof foydaga nisbati TBPH (Theravance)|AQST - Narxning foydaga nisbati|scPharmaceuticals (SCPH) - Narx-foyda koeffitsiyenti|TECX: P/E multiplikatori|Narx-foyda multiplikatori TNXP|Narxning foydaga nisbati China SXT Pharmaceuticals, Inc.|EPRX: Kompaniya qiymatining sof foydaga nisbati|P/E multiplikatori BHST|EXOZ - Kapitalizatsiyaning foydaga nisbati|P/E multiplikatori ORMP (oramed.com)|P/E multiplikatori enterabio.com ENTX|HYFT - Narxning foydaga nisbati|Biznesning o‘zini qoplash muddati ABVC BioPharma, Inc ABVC|CPIX: P/E multiplikatori|Quantum BioPharma Ltd - Kompaniya qiymatining sof foydaga nisbati|Narx-foyda koeffitsiyenti FGEN|Telomir Pharmaceuticals, Inc. - Kapitalizatsiyaning sof foydaga nisbati|P/E multiplikatori RANI|SNYR (Synergy CHC) - Kompaniya qiymatining sof foydaga nisbati|Narxning foydaga nisbati Rallybio RLYB|Lexaria Bioscience (LEXX) - Kapitalizatsiyaning foydaga nisbati|PULM - Narxning foydaga nisbati|Biznesning o‘zini qoplash muddati Pheton Holdings PTHL|APM (Aptorum) - Narx-foyda koeffitsiyenti|Lyra Therapeutics, Inc. (LYRA) - P/E multiplikatori|IBO (impactbiomedinc.com) - P/E multiplikatori|TNFA (TNF Pharmaceuticals) - Bozor narxining sof foydaga nisbati|Narxning foydaga nisbati cbdmd.com (YCBD)|Biznesning o‘zini qoplash muddati PainReform Ltd|P/E multiplikatori CYTO (Altamira Therapeutics Ltd.)|Lipella Pharmaceuticals (LIPO) - Kapitalizatsiyaning foydaga nisbati|OPTN - Narxning foydaga nisbati|Pieris Pharmaceuticals - Bozor narxining sof foydaga nisbati|PROC (Procaps Group) - Narx-foyda koeffitsiyenti|PTPI - Biznesning o‘zini qoplash muddati|Narxning foydaga nisbati Qilian International Holding Group Limited|SLRN: Kompaniya qiymatining sof foydaga nisbati|Narx-foyda koeffitsiyenti TFFP (TFF Pharma)